Animal data onlyNot FDA approved

PE-22-28 side effects

Also known as: PE 22-28 · PE22-28 · Mini-spadin · GVSWGLR · Gly-Val-Ser-Trp-Gly-Leu-Arg · PE 22-28 acetate

Updated Oct 24, 202621 sources

6 side effects reported for PE-22-28: 0 from studies and labels, 6 from users and guides. 2 come with the ways people manage them.

Cognitive

PE-22-28 overview

Side effects users and guides report

What people post and what dosing guides list. These are reports, not measured rates.

From users and guides6

Community reports, competitor and vendor guides, media.

Lethargy or sedation
The most commonly reported complaint, mostly above about 500 to 600 mcg a day
How people manage it
- Community reports hold the dose at or under 400 mcg and take it in the morning
Nasal irritation
Reported occasionally with nasal use; a clinic calls it the most common effect of that route, fading within the first week
Mild headache
Occasionally in the first few days, usually settles on its own
Mild fatigue early on
Some report it in the first week
Injection-site redness or tenderness
Occasional, minor
How people manage it
- Rotate sites
Heart, pain and seizure pathways (theoretical)
No reports; TREK-1 sits in heart and pain signalling, and mice lacking TREK-1 seize more easily. In mice PE-22-28 left the hERG heart channel alone.

Who should avoid it, and what not to combine

Prescribed antidepressantsSubstance
No interaction study exists for PE-22-28 with SSRIs or other antidepressants.
Epilepsy or seizure historyCondition
Mice lacking TREK-1 are more seizure-prone, and PE-22-28 blocks TREK-1. Untested, but the mechanism points this way.

How much is known

Animal data only

Animal and cell studies only, all from the group that developed it: mouse antidepressant-like effects and hippocampal neurogenesis after 4 days at 3 to 4 mcg/kg, and protection in a mouse stroke model. No human pharmacokinetic, safety or efficacy study exists.